Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.44M | -55.47M | -81.66M | -75.96M | -69.17M |
| Total Depreciation and Amortization | 13.00K | 3.00K | -- | -- | -- |
| Total Amortization of Deferred Charges | 186.00K | 36.07M | 36.07M | 37.41M | 38.02M |
| Total Other Non-Cash Items | 1.44M | -19.27M | 12.74M | 12.66M | 12.60M |
| Change in Net Operating Assets | 3.43M | -505.00K | 689.00K | 2.30M | -2.13M |
| Cash from Operations | -38.37M | -39.16M | -32.16M | -23.59M | -20.67M |
| Capital Expenditure | -200.00K | -183.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.52M | -34.52M | -- | -- | -- |
| Cash from Investing | -19.72M | -34.71M | -- | -- | -- |
| Total Debt Issued | 7.50M | 17.47M | 17.47M | 22.47M | 19.97M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 42.00M | 2.00K | 3.00K | 3.00K | 3.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 0.00 | 1.59M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 105.51M | 97.37M | 97.37M | 97.35M | -2.42M |
| Cash from Financing | 155.01M | 114.84M | 114.85M | 119.83M | 19.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.91M | 40.97M | 82.69M | 96.24M | -1.53M |